View Author
scopus: 23110217800

Kok, I.M.C.M. de

(Inge de Kok de)


cancer screening vaccination health incidence women netherland cost-effectiveness effect hpv vaccination mortality cancer screening vaccine cost-effectiveness ratio life years health care costs death increase ratio study number dutch trend analysis result group discounting cancer incidence non-cervical hpv-positive cancers price cohort threshold decrease smear table country infection period programme non-cervical papillomaviru healthcare costs hpv infections lesion situation population level intervention european analyses impact program chapter model screening programme van ballegooijen m cytology hpv-positive disease change life year prevention screening program assumption dutch situation healthcare treatment vaccine dose mortality rates cost-effectiveness analysis evaluation cost-effectiveness analyses figure stage saving cause interval ballegooijen health effects threshold price




10 Most Recent Publications

Primary screening for human papillomavirus compared with cytology screening for cervical cancer in European settings: cost effectiveness analysis based on a Dutch microsimulation model (Article)
Kok, I.M.C.M. de Rosmalen, J.M. van Dillner, J. Arbyn, M. Sasieni, P. Ballegooijen, M. van
2012-03-01
Practical implications of differential discounting of costs and health effects in cost-effectiveness analysis (Article)
O'Mahony, J.F. Kok, I.M.C.M. de Rosmalen, J.M. van Habbema, J.D.F. Brouwer, W.B.F. Ballegooijen, M. van
2011-12-01
Practical implications of differential discounting in cost-effectiveness analyses with varying numbers of cohorts (Article)
O'Mahony, J.F. Kok, I.M.C.M. de Rosmalen, J.M. van Habbema, J.D.F. Brouwer, W.B.F. Ballegooijen, M. van
2011-06-01
Trends in cervical cancer in the Netherlands until 2007: Has the bottom been reached? (Article)
Kok, I.M.C.M. de Aa, M.A.E.M. van der Ballegooijen, M. van Siesling, S. Karim-Kos, H.E. Kemenade, F. van Coebergh, J.W.W.
2011-05-01
Vaccination and Screening for the Prevention of Cervical Cancer: Health Effects and Cost-effectiveness (Doctoral Thesis)
Kok, I.M.C.M. de
2011-02-16
Would the effect of HPV vaccination on non-cervical HPV-positive cancers make the difference for its cost-effectiveness? (Article)
Kok, I.M.C.M. de Habbema, J.D.F. Rosmalen, J.M. van Ballegooijen, M. van
2011-02-01
Response (Article)
Kok, I.M.C.M. de Ballegooijen, M. van Habbema, J.D.F.
2010-03-01
Response Re: Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands. (Article)
Kok, I.M.C.M. de Ballegooijen, M. van Habbema, J.D.F.
2010-03-01
The challenges of organising cervical screening programmes in the 15 old member states of the European Union (Article)
Arbyn, M. Rebolj, M. Kok, I.M.C.M. de Fender, M. Becker, N. O'Reilly, M. Andrae, B.
2009-10-01
Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands (Article)
Kok, I.M.C.M. de Ballegooijen, M. van Habbema, J.D.F.
2009-08-01
  • rss icon RSS Publication Feed
  • foaf icon FOAF Profile